B-cell Acute Lymphoblastic Leukemia: Clinical Trials

55 trials for B-cell Acute Lymphoblastic Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 recruiting, 15 unknown, 5 active not recruiting, 5 completed. 55 Phase 1, 21 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 155Recruiting 19, Unknown 15, Active not recruiting 5, Completed 5, Not yet recruiting 5, Withdrawn 3, Terminated 2, Suspended 1
Phase 221Recruiting 8, Unknown 4, Withdrawn 3, Active not recruiting 2, Completed 2, Not yet recruiting 2

Follow B-cell Acute Lymphoblastic Leukemia: new trials by email Literature Review of B-cell Acute Lymphoblastic Leukemia trials Research Report on B-cell Acute Lymphoblastic Leukemia

Trials (filtered) newest first · largest first

All 55 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study Of KITE-753 in R/R B-Cell ALL
KITE-753 - B-cell Acute Lymphoblastic Leukemia
Phase 1Not yet recruitingM.D. Anderson Cancer Center182026-12-312026-09-11
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Phase 1 / Phase 2Not yet recruitingBeOne Medicines302026-12-012026-10-26
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult
Phase 1 / Phase 2Not yet recruitingMemorial Sloan Kettering Cancer Center262026-12-012026-11-09
CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
CD19-Targeted In Vivo CAR-T Injection (first infusion, Day 0); CD22 -Targeted In Vivo CAR-T Injection (second infusion, Day 7) - Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, In Vivo CAR-T
Phase 1RecruitingLiping Dou122026-09-012026-11-10
NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
Antigen-specific T cells CART/CTL and DCvac - B-Cell Acute Lymphoblastic Leukemia
Phase 1TerminatedShenzhen Geno-Immune Medical Institute102026-06-012026-11-02
Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
Anti-CD19/CD22 Dual-Target Cord Blood CAR-T Cells, Fludarabine, Cyclophosphamide - B-cell Acute Lymphoblastic Leukemia
Phase 1RecruitingRuijin Hospital182026-05-132026-09-25
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy - B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
Phase 1RecruitingBeijing GoBroad Hospital482026-03-152026-03-09
A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
Blinatumomab, Mini-CVD, MTX/ARA-C - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center32026-01-302026-08-18
Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2RecruitingLiping Dou202026-01-012026-06-15
Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia
CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2RecruitingLiping Dou302026-01-012026-06-25
A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Chimeric Antigen Receptor T Cells (CAR-T) - B-cell Acute Lymphoblastic Leukemia
Phase 1Not yet recruitingShanghai Tongji Hospital, Tongji University School of Medicine362025-07-102025-06-29
A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
HY004, Cyclophosphamide, Fludarabine Phosphate - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2WithdrawnJuventas Cell Therapy Ltd.2025-06-302025-08-08
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Phase 1 / Phase 2RecruitingVironexis Biotherapeutics Inc.322025-05-302026-10-26
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone - B-cell Acute Lymphoblastic Leukemia
Phase 1RecruitingChildren's Hospital Medical Center, Cincinnati282025-05-212026-02-18
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
DuoCAR20.19.22-D95, Fludarabine (Conditional therapy), Cyclophosphamide (Conditional therapy) - B-Cell Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Phase 1RecruitingUniversity of Kansas Medical Center542025-03-312026-05-14
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
CLIC-2201 - B-Cell Leukemia, Non-Hodgkin's Lymphoma
Phase 1RecruitingBritish Columbia Cancer Agency242025-01-022026-10-14
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
CD19x22 CAR T - B-cell Acute Lymphoblastic Leukemia
Phase 1RecruitingUniversity of Colorado, Denver532024-09-272025-11-28
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
YK012 - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2RecruitingExcyte Biopharma Ltd462024-09-252026-02-06
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Zilovertamab vedotin - B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
Phase 1 / Phase 2RecruitingMerck Sharp & Dohme LLC902024-08-162026-10-30
Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL
CD19-CAR_Lenti_ALLO - B-cell Acute Lymphoblastic Leukemia
Phase 1RecruitingBambino Gesù Hospital and Research Institute242024-04-282026-10-20

Showing 20 of 55. Sign in to see all of them.

Narrower conditions

Burkitt Lymphoma (55)  ·  Lymphoma, B-Cell (11)  ·  Recurrence (6)  ·  Lymphoma, Non-Hodgkin (5)  ·  Lymphoma (4)  ·  Lymphoma, Large B-Cell, Diffuse (4)  ·  Lymphoma, Mantle-Cell (4)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (4)  ·  Leukemia (3)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (3)  ·  Leukemia, Myeloid, Acute (3)  ·  Hematologic Diseases (2)  ·  Leukemia, B-Cell (2)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2)  ·  Lymphoma, Follicular (2)

Broader conditions

DNA Virus Infections (55)  ·  Epstein-Barr Virus Infections (55)  ·  Hemic and Lymphatic Diseases (55)  ·  Herpesviridae Infections (55)  ·  Immune System Diseases (55)  ·  Immunoproliferative Disorders (55)  ·  Infections (55)  ·  Lymphatic Diseases (55)  ·  Lymphoproliferative Disorders (55)  ·  Neoplasms by Histologic Type (55)  ·  Tumor Virus Infections (55)  ·  Virus Diseases (55)  ·  Neoplasms (54)  ·  Lymphoma (51)  ·  Lymphoma, Non-Hodgkin (50)

Interventions

Cyclophosphamide (8)  ·  fludarabine (7)  ·  Dexamethasone (4)  ·  Inotuzumab Ozogamicin (4)  ·  blinatumomab (4)  ·  Immunotherapy, Adoptive (3)  ·  Cytarabine (2)  ·  Etoposide (2)  ·  Injections (2)  ·  Prednisone (2)  ·  fludarabine phosphate (2)  ·  tocilizumab (2)  ·  venetoclax (2)  ·  Alemtuzumab (1)  ·  Azacitidine (1)

Sponsors

Liping Dou (3)  ·  Juventas Cell Therapy Ltd. (2)  ·  M.D. Anderson Cancer Center (2)  ·  University of Colorado, Denver (2)  ·  Yan'an Affiliated Hospital of Kunming Medical University (2)  ·  920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1)  ·  Anhui Provincial Hospital (1)  ·  Autolus Limited (1)  ·  Bambino Gesù Hospital and Research Institute (1)  ·  BeOne Medicines (1)  ·  Beijing GoBroad Hospital (1)  ·  Belarusian Research Center for Pediatric Oncology, Hematology and Immunology (1)  ·  BioCryst Pharmaceuticals (1)  ·  Bioceltech Therapeutics, Ltd. (1)  ·  British Columbia Cancer Agency (1)

Countries

China (23)  ·  United States (20)  ·  Australia (3)  ·  France (3)  ·  United Kingdom (3)  ·  Canada (2)  ·  Italy (2)  ·  South Korea (2)  ·  Taiwan (2)  ·  Belarus (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Chile (1)  ·  Colombia (1)  ·  Czechia (1)

Top investigators

Aibin Liang MD,Ph.D. (1)  ·  Dario Campana (1)  ·  David Shook, MD (1)  ·  Elias Jabbour, MD (1)  ·  Franco Locatelli, MD, PhD (1)  ·  He Huang, PhD (1)  ·  Jae Park, MD (1)  ·  Jeremy Rubinstein, MD, PhD (1)  ·  Jianxiang Wang M.D. (1)  ·  Jie Jin, MD (1)  ·  John Byon, MD, PhD (1)  ·  Joseph McGuirk, D.O. (1)  ·  Kevin Hay, MD (1)  ·  Li Li, MD (1)  ·  Lihua Yang (1)

Results publications

PMID 28054442, PMID 33308471, PMID 34893603, PMID 36228643, PMID 36821767, PMID 37647601, PMID 40367950, PMID 41671463, PMID 42789493

NIH funding

2016 (2), 2023 (1)